Table 1 The characteristics of the included studies
| Â | Study | YEAR | Country | Species | Sex | Animal disease model | Target receptor |
|---|---|---|---|---|---|---|---|
1 | Janiak P | 2007 | France | Rat | Male | Obese fa/fa Zucker rats | CB1R antagonist |
2 | Federica B | 2010 | Italy | Mouse | Male | STZ-induced diabete C57BL7/J mice | CB1R antagonist |
3 | Partha M | 2010 | USA | Mouse | Male | Cisplatin-induced renal dysfunction C57BL/7Â J mice | CB1R antagonist, genetic deletion of CB1R |
4 | Partha M2 | 2010 | USA | Mouse | Male | Cisplatin-induced renal dysfunction C57BL/7Â J mice | CB2R knockout, CB2R agonist |
5 | James C | 2010 | Canada | Rat | Male | JCR:LA-cp obese cp/cp rats | CB1R antagonist |
6 | Federica B | 2011 | Italy | Mouse | Male | STZ-induced diabete C57BL7/J mice | CB2R agonist |
7 | Mónica A | 2012 | Spain | Rat | Male | Diet-induced obesity Wistar rats | CB1R antagonist |
8 | Béla H | 2012 | USA | Mouse | Male | Cisplatin-induced renal dysfunction C57BL/7 J mice | CB2R knockout, CB2R agonist |
9 | D. H. Nam | 2012 | Korea | Mouse | Male | db/db diabetic mice | CB1R antagonist |
10 | Tang Y | 2012 | USA | Mouse | Male | Diet-induced obese AKR/J Mice | CB1R-ASO |
11 | Federica B | 2014 | Italy | Mouse | Male | STZ-induced diabete C57BL7/J mice | CB2R knockout |
12 | Jourdan T | 2014 | USA | Rat | Male | Zucker Diabetic Fatty rats | Peripheral CB1R antagonist |
13 | Chun-L L | 2014 | China (Taiwan) | Rat and Mouse | Male | STZ-induced diabete rats and FVB/N mice | CB1R transgenic,CB1R antagonist and CB1R ASO |
14 | Yung-C H | 2015 | China (Taiwan) | Rat and Mouse | Male | Wistar rats | CB1R transgenic, CB1R agonist |
15 | Kayte A | 2015 | Australia | Rat | Male | Diet-induced obesity Sprague–Dawley rats | CB1R antagonist |
16 | Lola L | 2015 | France | Mouse | Unclear | UUO renal fibrosis | CB1R antagonist |
17 | Chih-Y L | 2015 | China (Taiwan) | Mouse | Male | Partial nephrectomy uremia | CB1R antagonist |
18 | Kayte A | 2016 | Australia | Rat | Male | Diet-induced obesity Sprague–Dawley rats | CB2R agonist |
19 | Partha M | 2016 | USA | Mouse | Male | Cisplatin-induced renal dysfunction C57BL/7Â J mice | CB2R agonist, CB2R knockout |
20 | Carlamaria Z | 2016 | Italy | Mouse | Male | BTBR ob/ob mice | CB2R agonist |
21 | Jourdan T | 2017 | USA | Rat | Male | Zucker diabetic fatty rats | Global deletion of CB1R |
22 | Shiran U | 2017 | Israel | Mouse | Male | High-fat diet mice | Renal proximal tubular cells-specific CB1R-null |
23 | F Barutta | 2018 | Italy | Mouse | Male | STZ-induced diabete C57BL7/J mice | Peripheral CB1R antagonist |
24 | Liad H | 2018 | Israel | Mouse | Male | STZ and Akita mice | Peripheral CB1R antagonist |
25 | Jourdan T | 2018 | USA | Mouse | Male | STZ-induced diabete C57BL7/J mice | Podocyte-specific Cnr1 deletion |
26 | Jeffrey D | 2018 | India | Mouse | Male | Ischemia–reperfusion injury C57BL/7 J mice | CB2R agonist |
27 | Li Z | 2018 | China | Mouse | Male | UUO and UIRI male BALB/c mice | CB2R inverse agonist |
28 | Murat Ç | 2019 | Turkey | Rat | Male | Renal ischemia reperfusion Sprague–Dawley rats | CB2R agonist |
29 | Eszter T | 2020 | USA | Mouse | Male | C57BL/6Â J male mice of HRS, induced by BDL | CB2R agonist |
30 | Shiran U | 2020 | Israel | Mouse | Male | High-fat diet mice | Peripheral CB1R antagonist |
31 | Isabel G | 2021 | Spain | Mouse | Male | STZ-induced diabete C57BL7/J mice | Dual CB1R antagonist/CB2R agonist CBD |
32 | Jayarami R | 2021 | India | Rat | Unclear | STZ-induced diabete rats | Peripheral CB1R antagonist |
33 | Li Z | 2021 | China | Rat | Male | Chronic intermittent hypoxia Sprague–Dawley rat | CB1R antagonist |
34 | Shan Z | 2021 | China | Mouse | Male | Unilateral nephrectomy and D-gal aged C57BL/7 mice | CB2R knockout |
35 | Shan Z2 | 2021 | China | Mouse | Male | UIRI and UUO C57BL/7 mice | CB2R agonist |